MICHAEL ANDREEFF, M.D.
Osteopathic Medicine at Holcombe Blvd, Houston, TX
License number
Texas H9035
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about MICHAEL ANDREEFF at radaris.comName
Address
Phone
1515 Holcombe Blvd, Houston, TX 77030
2715 Pemberton Dr, Houston, TX 77005
Organization information
See more information about MICHAEL ANDREEFF at bizstanding.comUniversity TX MD Anderson Cancer Center - Michael Andreeff MD
1515 Holcombe Blvd UNIT 207, Houston, TX 77030
Categories:
Hematology Physicians & Surgeons
Site:
Phone:
(713) 792-6161 (Phone)
Michael Andreeff MD,PHD
1515 Holcombe Blvd, Houston, TX 77030
Industry:
Internist
Phone:
(713) 792-6161 (Phone)
Michael Andreeff
Professional information
Professor At Ut Mdacc
Position:
Professor of Medicine and Haas Chair in Genetics at MDACC
Location:
Houston, Texas Area
Industry:
Hospital & Health Care
Work:
MDACC
- University of Texas MD Anderson Cancer Center since 1990
-
Professor of Medicine and Haas Chair in Genetics
Memorial Sloan-Kettering Cancer Center
1977 - 1990
-
Associate Professor of Medicine; Head, Leukemia Biology
Education:
University of Heidelberg Medical School
MD,PhD, Medicine
MD,PhD, Medicine
Michael Andreeff, Houston TX
Specialties:
Internal Medicine, Hematology & Oncology, Hematology, Medical Oncology, Hematology
Work:
M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030
1515 Holcombe Blvd, Houston, TX 77030
Education:
Medizinische Universitat Vienna (1965)
Dr. Michael Andreeff, Houston TX - MD (Doctor of Medicine)
Address:
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
(713) 792-2121 (Phone), (713) 794-5492 (Fax)
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
(713) 792-2121 (Phone)
1515 Holcombe Blvd, Houston 77030
(713) 792-2121 (Phone), (713) 794-5492 (Fax)
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
(713) 792-2121 (Phone)
Hospitals:
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
1515 Holcombe Blvd, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
Education:
Medical Schools
Tufts University
Tufts University
Michael Andreeff, Houston TX
Specialties:
Hematologist
Address:
1515 Holcombe Blvd, Houston, TX 77030
Phosphorylation And Regulation Of Akt/Pkb By The Rictor-Mtor Complex
US Patent:
2010017, Jul 8, 2010
Filed:
Jul 15, 2008
Appl. No.:
12/218629
Inventors:
David M. Sabatini - Cambridge MA, US
Dos D. Sarbassov - Shrewsbury MA, US
Michael Andreeff - Houston TX, US
Marina Konopleva - Houston TX, US
Zhihong Zeng - Houston TX, US
Francis J. Giles - San Antonio TX, US
Dos D. Sarbassov - Shrewsbury MA, US
Michael Andreeff - Houston TX, US
Marina Konopleva - Houston TX, US
Zhihong Zeng - Houston TX, US
Francis J. Giles - San Antonio TX, US
International Classification:
A61K 31/436, C12N 5/00, C12Q 1/02, A61P 35/00
US Classification:
514291, 435375, 435 29
Abstract:
In certain aspects, the invention relates to methods for identifying compounds which modulate Akt activity mediated by the rictor-mTOR complex and methods for treating or preventing a disorder that is associated with aberrant Akt activity.
Combination Therapy With Synthetic Triterpenoids And Gemcitabine
US Patent:
2009004, Feb 19, 2009
Filed:
Aug 15, 2008
Appl. No.:
12/192710
Inventors:
Colin Meyer - Frisco TX, US
Michael Andreeff - Houston TX, US
Marina Konopleva - Houston TX, US
Michael Andreeff - Houston TX, US
Marina Konopleva - Houston TX, US
International Classification:
A61K 31/7064, A61P 35/00
US Classification:
514 49
Abstract:
The present invention concerns methods for treating cancer, such as pancreatic cancer, using combination therapies, including the combination of a synthetic triterpenoid, e.g., CDDO-Me, and gemcitabine.
Local Production And/Or Delivery Of Anti-Cancer Agents By Stromal Cell Precursors
US Patent:
2004007, Apr 22, 2004
Filed:
Feb 28, 2003
Appl. No.:
10/377276
Inventors:
Matus Studeny - Bratislava, SK
Michael Andreeff - Houston TX, US
Frank Marini - Houston TX, US
Michael Andreeff - Houston TX, US
Frank Marini - Houston TX, US
Assignee:
Board of Regents, The University of Texas System
International Classification:
A61K048/00, C12N005/08, C12N015/86
US Classification:
424/093210, 435/456000, 435/366000
Abstract:
The present invention concerns the use of compositions comprising, and methods for making, genetically modified mesenchymal stem cells to treat subjects with hyperproliferative disorders. Certain embodiments allow local delivery of an agent while avoiding systemic delivery of the agent alone. Stromat precursor cells may be used to produce a biological agent locally at tumor sites. The tumor microenvironment, or other proliferation inducing microenvironment, preferentially promotes the engraftment of stromal precursors as compared to other tissues.
Method Of Cancer Treatment
US Patent:
2004005, Mar 25, 2004
Filed:
Apr 18, 2003
Appl. No.:
10/419025
Inventors:
Michael Andreeff - Houston TX, US
Elihu Estey - Houston TX, US
Elihu Estey - Houston TX, US
Assignee:
Board of Regents, The University of Texas System
International Classification:
A61K009/127, G01N033/574
US Classification:
424/450000, 435/007230
Abstract:
This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of (a) evaluating the subject to determine if the subject has relapsed or refractory cancer; (b) administering a high-dose amount of liposomal-annamycin for at least 3 days in a 7 day period. First line cancer therapy with particular reference to leukemia is both contemplated and useful.
Cddo-Compounds And Combination Therapies Thereof
US Patent:
7795305, Sep 14, 2010
Filed:
Oct 10, 2008
Appl. No.:
12/249588
Inventors:
Marina Konopleva - Houston TX, US
Michael Andreeff - Houston TX, US
Michael B. Sporn - Tunbridge VT, US
Michael Andreeff - Houston TX, US
Michael B. Sporn - Tunbridge VT, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
The Trustees of Dartmouth College - Hanover NH
The Trustees of Dartmouth College - Hanover NH
International Classification:
A61K 31/21
US Classification:
514510, 514310, 514569
Abstract:
CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.
Method Of Cancer Treatment
US Patent:
7204996, Apr 17, 2007
Filed:
Jun 10, 2005
Appl. No.:
11/150461
Inventors:
Michael Andreeff - Houston TX, US
Elihu H Estey - Houston TX, US
Elihu H Estey - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 9/127
US Classification:
424450, 514 25, 514 33, 514 34
Abstract:
This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of.